The inno­v­a­tive 3D screen print­ing tech­nol­ogy from Laxxon Med­ical Corp. opens up new, pre­vi­ously unknown pos­si­bil­i­ties for opti­mized and inno­v­a­tive drug deliv­ery sys­tems (DDS) for phar­ma­ceu­ti­cal com­pa­nies in their prod­uct devel­op­ment and pro­duc­tion processes. This makes it pos­si­ble for the first time to pro­duce drugs in oral, trans­der­mal and implantable dosage forms with cus­tomized drug release.